Deriving rules and assertions from pharmacogenomics knowledge resources in support of patient drug metabolism efficacy predictions

Journal of the American Medical Informatics Association

Volumn 19, Issue 5, 2012, Pages 840-850

  Overby, Casey Lynnette ^a   Devine, Emily Beth ^a,b   Tarczy Hornoch, Peter ^a,c   Kalet, Ira J ^a,b,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOXIFEN; NORTAMOXIFEN; TAMOXIFEN; 4-HYDROXY-N-DESMETHYLTAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; N-DESMETHYLTAMOXIFEN;

ALGORITHM; ALLELE; ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; GENE; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HUMAN; KNOWLEDGE; PHARMACOGENOMICS; PHENOTYPE; PREDICTION; SCORING SYSTEM; BIOLOGICAL MODEL; BIOTRANSFORMATION; BLOOD; BREAST TUMOR; COMPUTER ASSISTED DRUG THERAPY; EXPERT SYSTEM; GENETICS; KNOWLEDGE BASE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTIVE VALUE; REPRODUCIBILITY; STATISTICAL MODEL; VALIDATION STUDY;

ALGORITHMS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOTRANSFORMATION; BREAST NEOPLASMS; DRUG THERAPY, COMPUTER-ASSISTED; EXPERT SYSTEMS; HUMANS; INDIVIDUALIZED MEDICINE; KNOWLEDGE BASES; LINEAR MODELS; MODELS, GENETIC; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TAMOXIFEN;

EID: 85047688633     PISSN: 10675027     EISSN: 1527974X     Source Type: Journal    
DOI: 10.1136/amiajnl-2011-000405     Document Type: Article

References (23)

1. Preissner S, Kroll K, Dunkel M, et al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res 2010;38(Database issue):D237-43.
2. Sheffield LJ, Pillimore HE. Clinical use of pharmacogenomic tests in 2009. Clin Biochem Rev 2009;30:55-65.
3. Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: an overview of the PharmGKB Project. Pharmacogenomics J 2001;1:167-70.
4. Dawood S, Leyland-Jones B. Pharmacology and pharmacogenetics of chemotherapeutic agents. Cancer Invest 2009;27:482-8.
5. Kane-Gill SL, Van Den Bos J, Handler SM. Adverse drug reactions in hospital and ambulatory care settings identified using a large administrative database. Ann Pharmacother 2010;44:983-93.
6. Budnitz DS, Pollock DA, Weidenbach KN, et al. National surveillance of emergency department visits for outpatient adverse drug events. JAMA 2006;296:1858-66.
7. Boyce R, Collins C, Horn J, et al. Computing with evidence Part II: an evidential approach to predicting metabolic drug-drug interactions. J Biomed Inform 2009;42:990-1003.
8. Boyce R, Collins C, Horn J, et al. Computing with evidence Part I: a drug-mechanism evidence taxonomy oriented toward confidence assignment. J Biomed Inform 2009;42:979-89.
9. Borges S, Desta Z, Jin Y, et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010;50:450-8.
10. Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008;83:234-42.
11. Zineh I, Beitelshees AL, Gaedigk A, et al. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther 2004;76:536-44.
12. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37.
13. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74.
14. Fuhr U. Pharmacogenetic-based clinical scores: a useful, simple tool to predict tamoxifen-based CYP2D6 phenotype? J Clin Pharmacol 2010;50:370-2.
15. Consortium on Breast Cancer Pharmacogenomics profile. http://www. pharmgkb.org/contributors/pgrnAlumni/cobra_profile.jsp (accessed 5 May 2011).
16. Consortium on Breast Cancer Pharmacogenomics (COBRA). Patient responses to tamoxifen. Submission PS202620 [Computer file]. Consortium on breast cancer pharmacogenomics (COBRA) [producer], 2006. PharmGKB [distributor], 2006.
17. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64.
18. Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP5A and CYP2D6. J Pharmacol Exp Ther 2004;310:10062-75.
19. Java Expert System Shell. http://www.jessrules.com (accessed 5 May 2011).
20. Kiyotani K, Mushiroda T, Imamura CK, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010;28:1287-93
21. Gjerde J, Hauglid M, Breilid H, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008;19:56-61.
22. Rae JM, Drury S, Hayes DF, et al. Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. 33rd Annual San Antonio Breast Cancer Symposium. Abstract S1-7. Presented 9 December 2010.
23. Leyland-Jones B, Regan MM, Bouzk M, et al: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. 33rd Annual San Antonio Breast Cancer Symposium. Abstract S1-8. Presented 9 December 2010.